Condition: West Nile Virus · West Nile Fever Encephalitis · West Nile Fever Myelitis · Sponsor: Tel-Aviv Sourasky Medical Center
West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease. The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.
This description comes directly from the study's public registry record.
David Hagin, MD PhD · 972524792296 · Davidha@tlvmc.gov.il
Dania Dror, B.Nutr; MPH · 97236974679 · Daniad@tlvmc.gov.il
Always discuss trial participation with your own doctor first.
| Tel-Aviv Sourasky Medical Center | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06510426